Reappointment of Ms. Bokara Nagarajan Padmaja Priyadarshini (DIN: 06416242) as an Independent Director for a period of five years
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's board, at its meeting on August 30, 2025, approved several key items including the scheduling of the 33rd AGM on September 29, 2025. The board approved the disinvestment from its material subsidiary Dindigul Farm Product Limited (DFPL), which contributed Rs. 6,282.81 lakhs (~47.11%) of consolidated turnover and Rs. 3,521.13 lakhs (~35.24%) of consolidated net worth as of March 31, 2025, along with reclassifying its status from promoter to public. The authorised share capital was increased to Rs. 85 crores (8.5 crore equity shares of Rs. 10 each). Three Whole-time Directors (Mr. Swaminathan, Mr. Singarababu Indirakumar, Mr. Muthukrishnan Ramesh) were appointed for five-year terms, and Dr. Bokara Nagarajan Padmaja Priyadarshini was appointed as Independent Director for five years. The board also approved material related party transactions of up to Rs. 25 crores each with six subsidiaries, and appointed M/s Chandra Sekaran M S & Co as Internal Auditor and Mr. K. Ravichandran as Secretarial Auditor.
The disinvestment of DFPL, which contributes nearly half of consolidated revenue, is a significant structural change that could materially reshape the company's financials and focus. The increase in authorised capital signals potential fundraising plans, while the multiple related party transactions with subsidiaries indicate active intra-group dealings that shareholders should monitor closely.